Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Canakinumab for Treatment of Adult-onset Still's Disease (CONSIDER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02204293
Recruitment Status : Terminated (Recruitment issues due to marketing authorization of study drug)
First Posted : July 30, 2014
Results First Posted : August 7, 2020
Last Update Posted : August 7, 2020
Sponsor:
Information provided by (Responsible Party):
Eugen Feist, Charite University, Berlin, Germany

Brief Summary:
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.

Condition or disease Intervention/treatment Phase
Adult-Onset Still´s Disease Drug: Canakinumab Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Actual Study Start Date : June 21, 2012
Actual Primary Completion Date : May 5, 2018
Actual Study Completion Date : May 5, 2018


Arm Intervention/treatment
Experimental: Canakinumab
Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
Drug: Canakinumab
Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
Other Name: Ilaris

Placebo Comparator: Placebo
Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
Drug: Canakinumab
Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
Other Name: Ilaris

Drug: Placebo
Matching placebo administered subcutaneously.




Primary Outcome Measures :
  1. Core Study Part I: Percentage of Responders as Assessed by Disease Activity Score 28 Joints (DAS28) Score at Week 12 [ Time Frame: Week 12 ]
    Responders included participants with change in disease activity score based on 28 joint counts and ESR (DAS28) score > 1.2. The DAS28 score index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity score, and the erythrocyte sedimentation rate (ESR) value. Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission.


Secondary Outcome Measures :
  1. Core Study Part I: Change From Baseline (CFB) in Disease Activity Score 28 Joints Erythrocyte Sedimentation Rate (DAS28 [ESR]) Score [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity score, and ESR value.Total score ranged between 0-10. A DAS28-ESR score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. Least squares (LS) mean was calculated by mixed linear model for repeated measures (MMRM) analyses.

  2. Core Study Part I: CFB in DAS28 C-reactive Protein (CRP) Score [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity score, and CRP value. Total score ranged between 0-10. A DAS28-CRP score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission. A positive change in score indicates worsening, and a negative change indicates improvement. LS mean was calculated by MMRM analyses.

  3. Core Study Part I: CFB in American College of Rheumatology (ACR) Component: 68 Tender Joint Count (TJC) [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    The 68 TJC included the 8 distal interphalangeal (IP), 10 proximal IP and 10 metacarpophalangeal (MTP) joints of hands, the 10 MTP and 10 proximal IP joints of feet, the 2 wrists, 2 elbows, 2 shoulders, 2 acromioclavicular, 2 sternoclavicular, 2 temporomandibular, 2 hip, 2 knee, 2 talo-tibial, and 2 mid-tarsal joints. Joint tenderness was graded present (1) or absent (0). Total score is calculated by adding the scores, which range from 0 (no tender joint) to 68 (all tender joints). Lower scores indicate no tender joint and higher scores indicate worsening tender joints. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.

  4. Core Study Part I: CFB in ACR Component: 66 Swollen Joint Count (SJC) [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    The 66 SJC included the 8 distal interphalangeal (IP), 10 proximal IP and 10 metacarpophalangeal (MTP) joints of hands, the 10 MTP and 10 proximal IP joints of feet, the 2 wrists, 2 elbows, 2 shoulders, 2 acromioclavicular, 2 sternoclavicular, 2 temporomandibular, 2 knee, 2 talo-tibial, and 2 mid-tarsal joints. Swelling was graded present (1) or absent (0). Total score is calculated by adding the scores, which range from 0 (no swollen joint) to 66 (all swollen joints). Lower scores indicate no swollen joint and higher scores indicate worsening swollen joints. A negative change in Baseline indicates improvement. LS mean was calculated by MMRM analyses.

  5. Core Study Part I: CFB in the 28 TJC [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    A total of 28 joints were assessed for tenderness. The number of tender joints could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity. LS mean was calculated by MMRM analyses.

  6. Core Study Part I: CFB in the 28 SJC [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    A total of 28 joints were assessed for swelling. The number of swollen joints could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity. LS mean was calculated by MMRM analyses.

  7. Core Study Part I: CFB in ACR Component: Acute Phase Reactant CRP [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    A negative change from Baseline in CRP level indicates an improvement. LS mean was calculated by MMRM analyses.

  8. Core Study Part I: CFB in ACR Component: Acute Phase Reactant ESR [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    A negative change from Baseline in ESR level indicates an improvement. LS mean was calculated by MMRM analyses.

  9. Core Study Part I: CFB in Serum Ferritin Level at Week 12 [ Time Frame: Week 12 ]
    LS mean was calculated by MMRM analyses.

  10. Core Study Part I: Percentage of Responders With Fever Episodes [ Time Frame: Week 12 ]
    Fever is defined as an oral or rectal body temperature greater than 38 degrees Celsius (°C).

  11. Core Study Part I: CFB in ACR Component: Physician's Global Assessment of Disease Activity Score [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    The physician's global assessment of disease activity was assessed using a numerical rating scale of 0-10 where 0= no disease activity and 10= activity to maximal disease activity. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.

  12. Core Study Part I: CFB in ACR Component: Participant's Global Assessment of Disease Activity Score [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    The participant's global assessment of disease activity was assessed using a numerical rating scale of 0-10, where 0= no disease activity and 10= maximal disease activity. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.

  13. Core Study Part I: CFB in ACR Component: Participant's Global Assessment of Pain Score [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
    The participant's global assessment of pain was assessed using a numerical rating scale of 0-10, where 0= no disease activity and 10= maximal disease activity. A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.

  14. Core Study Part I: CFB in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score [ Time Frame: Baseline, Week 12 ]
    The HAQ measures physical disability and functional status. It has 4 dimensions: disability, pain, drug side effects and dollar costs. The HAQ score is calculated by summing the computed scores for each category and dividing by the number of categories answered. It ranges from 0 (without any difficulty) to 3 (unable to do). A negative change from Baseline indicates improvement. LS mean was calculated by MMRM analyses.

  15. Core Study Part I: Percentage of Responders With American College of Rheumatology Response of 20 (ACR20) [ Time Frame: Baseline, Week 12 ]
    ACR20 response was defined as a ≥ 20% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.

  16. Core Study Part I: Percentage of Responders With ACR30 [ Time Frame: Baseline, Week 12 ]
    ACR30 response was defined as a ≥ 30% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.

  17. Core Study Part I: Percentage of Responders With Modified ACR30 [ Time Frame: Baseline, Week 12 ]
    A participant was considered responder if he/she had achieved the incidence of modified adapted response (ACR30 criteria) of at least a 30% improvement in no intermittent fever and had at least 30% improvement in at least 6 of the following 7 measures: tender and swollen 68-joint counts, participant's assessment of pain, participant's global assessment of disease activity, physician's global assessment of disease activity, participant's functional capacity (HAQ-DI score) and acute phase reactant- ESR. Participant were modified ACR30 responders at a given post-randomization visit if they satisfied the modified ACR30 criteria, respectively.

  18. Core Study Part I: Percentage of Responders With ACR50 [ Time Frame: Baseline, Week 12 ]
    ACR50 response was defined as a ≥ 50% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.

  19. Core Study Part I: Percentage of Responders With ACR70 [ Time Frame: Baseline, Week 12 ]
    ACR70 response was defined as a ≥ 70% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.

  20. Core Study Part I: Percentage of Responders With ACR90 [ Time Frame: Baseline, Week 12 ]
    ACR90 response was defined as a ≥ 90% improvement (reduction) compared with Baseline for both 68 TJC and 66 SJC, as well as for three of the additional five ACR core set variables: Participant's Assessment of Pain over the previous 24 hours: using a NRS left end of the line 0=no pain to right end of the line 10=unbearable pain; Participant's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a NRS where left end of the line 0=no disease activity to right end of the line 10=maximum disease activity; HAQ-DI 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant ESR.

  21. Core Study Part I: Percentage of Responders With European League Against Rheumatism (EULAR) Response [ Time Frame: Baseline, Week 12 ]
    EULAR response is based on DAS28-ESR and DAS28-CRP scores. The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, subject global assessment of disease activity score, and ESR or CRP value. A DAS28-CRP or ESR score of 5.1 or above = high disease activity, a value between 3.2 and 5.1 = moderate disease activity and value between 2.6 and 3.2 = low disease activity, value < 2.6 = disease remission. EULAR response has 3 categories: EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline < -1.2. EULAR Moderate response: DAS28 >3.2 to ≤ 5.1 or a change from Baseline < -0.6 to ≥ -1.2 or EULAR No response: DAS28 >5.1 or a change from Baseline < -0.6 to ≤ -1.2.

  22. Core Study Part I: Percentage of Responders Achieving Low Disease Activity (LDA) [ Time Frame: Week 12 ]
    Percentage of responders were defined as the participants who achieved LDA (DAS28 score < 3.2) at Week 12. The DAS28 index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, participant global assessment of disease activity score, and ESR or CRP value. Total score ranged between 0-10. A DAS28 score greater than 5.1 implies high disease activity, equal to or less than 3.2 low disease activity, and less than 2.6 remissions.

  23. Core Study Part I: Percentage of Responders Achieving Disease Remission and Extended Disease Remission [ Time Frame: Week 12 ]
    Participants with disease remission: LDA (DAS28 score< 2.6). The DAS28 index is a composite score of weighted components including both 28 TJC an SJC, participant global assessment of disease activity score, and ESR or CRP value. A DAS28 score greater than 5.1: high disease activity, ≤ 3.2: low disease activity, and less than 2.6: remission. Extended remission criteria included DAS28 < 2.6 and no signs of systemic activity for up to two consecutive study visits till Week 12 defined as any of Yamaguchi´s primary classification criteria for AOSD which included fever attacks at 39 °C for more than a week, arthralgia, salmon red, maculate, urticarial or maculo-papular rash and leukocytosis (white blood cells increase) of > 10000/cubic millimeters (mm^3) with > 80% neutrophils.

  24. Core Study Part I: Change in Joint Mobility (Degrees of Motion) Assessed by Neutral Zero Method [ Time Frame: Baseline, Week 12 ]
    Number of joints with limitation of motion according to neutral zero method was assessed which included mobility of joints (elbows, wrists, shoulder joints, hip joints, knee joints, and upper ankle joints) within the reference range/degree. Response is defined as an improvement of ≥ 30%, 50%, 70% and 90% from Baseline. A negative change score indicates improvement. LS mean was calculated by MMRM analyses.

  25. Core Study Part I: CFB in Medical Outcome Short Form (SF-36) Health Survey Score [ Time Frame: Baseline, Week 12 ]
    The SF-36 determines overall quality of life assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 contribute to physical component summary score (PCS). Items 5-8 contribute to mental component summary score (MCS). Scores on each item are summed and averaged (range = 0 "worst"-100 "best"). Positive numbers indicate improvement from Baseline. LS mean was calculated by MMRM analyses.

  26. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to Month 27 ]
    An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. AEs include symptoms of illnesses, as well as every unfavourable and unintended reaction. SAEs are AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written and signed consent from the participant to take part in the study
  2. Men and women aged ≥ 18 years and ≤ 75 years
  3. Fulfilment of AOSD classification criteria (according to Yamaguchi et al, J. Rheumatology, 1992)
  4. Disease activity based on Disease Activity Score 28 (DAS28) of ≥3.2 at screening
  5. At least 4 painful and 4 swollen joints at screening and baseline (of the 28 joints according to DAS28)
  6. If undergoing treatment with non-steroidal anti-inflammatory drugs (NSAIDs), stable dose for at least 4 weeks prior to randomisation
  7. If undergoing treatment with glucocorticoids, stable dose of ≤10 milligrams per day (mg/day) (prednisolone or equivalent) for at least 4 weeks prior to randomisation
  8. If undergoing treatment with conventional disease-modifying anti-rheumatic drugs (DMARD), stable dose for at least 3 months prior to randomisation
  9. Normalisation period for biological DMARDS (anakinra 1 week, etanercept 1 month, adalimumab and certolizumab 2 months, infliximab, golimumab, abatacept and tocilizumab 3 months, rituximab 9 months, canakinumab 6 months) prior to randomisation
  10. In participants of reproductive age, use of an effective method of contraception as well as negative pregnancy test prior to the study commencing.

Exclusion Criteria:

  1. Previous treatment with the study drug with repeated administration of canakinumab
  2. Intraarticular or intravenous administration of glucocorticoids within 4 weeks prior to the baseline or use of narcotic analgesics except for analgesics permitted within the framework of the investigation (codeine and tramadol)
  3. Presence of another, serious chronic-inflammatory disease
  4. Positive hepatitis B antigen (HBsAg), hepatitis C antibodies and/or human immunodeficiency virus (HIV) antibodies.
  5. Presence of a relevant, active infection or other diseases, which entail a tendency towards infection
  6. Positive screening for latent tuberculosis, in accordance with usual local practice
  7. Raised liver count (raised bilirubin; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3-fold the normal range)
  8. Serum-creatinine concentration >1.5 milligrams per deciliter (mg/dL)
  9. Inadequate haematological findings (hemoglobin [Hb] ≤ 10 grams per deciliter (g/dL), neutrophils ≤2,500/microliter (µl) and thrombocytes ≤100,000/µl)
  10. Simultaneous participation in any other interventional clinical study within the last 30 days preceding the commencement of the study
  11. History of neoplasia with the exception of a curatively treated non-melanoma skin tumour or carcinoma of the cervix treated in situ without any indication of recurrence within the last 10 years
  12. Relevant cardiac or pulmonary disorders
  13. Severe intercurrent neurological or psychiatric disorders
  14. Macrophage activation syndrome (MAS) as part of previous treatment with IL-1 blockade (e.g. anakinra, rilonacept)
  15. Vaccination with a live vaccine within 3 months before the baseline
  16. Alcohol or drug abuse in the past 12 months
  17. ≥400 milliliter (mL) donation of blood or loss up to 8 weeks before the baseline
  18. Pregnancy or breast-feeding
  19. Commitment of the patient to an institution at the direction of an authority or court

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02204293


Locations
Layout table for location information
Germany
Charité Campus Mitte
Berlin, Germany, 10117
Immanuel Krankenhaus Berlin
Berlin, Germany, 13125
Universität Erlangen
Erlangen, Germany, 91054
Kliniken Essen-Süd/Krankenhaus St. Josef
Essen, Germany, 45239
Universitätsklinikum der J.W. Goethe-Universität Frankfurt
Frankfurt a. M., Germany, 60590
Asklepios Klinikum Hamburg Altona
Hamburg, Germany, 22763
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Universitätsklinikum Heidelberg
Heidelberg, Germany, 69120
Universitätskrankenhaus Schleswig Holstein
Kiel, Germany, 24105
Med. Klinik I für Innere Medizin Köln
Köln, Germany, 50937
Klinikum der Universität München
München, Germany, 80336
Klinikum Südstadt Rostock
Rostock, Germany, 18059
Universitätsklinikum Tübingen
Tübingen, Germany, 72076
Fachkrankenhaus
Vogelsang, Germany, 39245
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
Layout table for investigator information
Principal Investigator: Eugen Feist, Prof. Dr. Charité University Berlin Germany
  Study Documents (Full-Text)

Documents provided by Eugen Feist, Charite University, Berlin, Germany:
Study Protocol  [PDF] October 20, 2017
Statistical Analysis Plan  [PDF] May 9, 2018

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eugen Feist, Prof. Dr Eugen Feist, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT02204293    
Other Study ID Numbers: CACZ885GDE01T
2011-001027-20 ( EudraCT Number )
First Posted: July 30, 2014    Key Record Dates
Results First Posted: August 7, 2020
Last Update Posted: August 7, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eugen Feist, Charite University, Berlin, Germany:
Adult-Onset Still´s Disease
Canakinumab
Joint involvement
AOSD
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Juvenile
Still's Disease, Adult-Onset
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Arthritis, Rheumatoid